Find this member on networks :

About

Frédéric Perros is a Research Director within the MERISM team at the Inserm U1060-CarMeN laboratory in Lyon, France. An expert in pulmonary vascular physiology and pathophysiology, he specializes in studying pulmonary hypertension. Since joining CarMeN, he has also been interested in the inter-organ dialogue between the liver and lungs.

Curriculum

Frédéric Perros obtained his doctorate in physiology and pathophysiology of the respiratory and circulatory systems in 2007 from the Université Paris-Sud (France). His doctoral research focused on the cellular and molecular aspects of pulmonary arterial hypertension (PAH). He then went on to do a post-doctorate in Professor Bart Lambrecht’s laboratory at Ghent University (Belgium), where he studied the immunopathology of asthma and PAH.

In 2009, Dr Perros joined the INSERM UMR-S999 unit headed by Professor Marc Humbert. There, he leads a research group dedicated to the physiology and pathophysiology of the pulmonary circulation. Between 2015 and 2016, he spent a year as a research associate in the pulmonary hypertension research group at the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) (Canada), studying the epigenetic mechanisms of PAH.

From 2020 to 2022, he headed team 2 of UMR-S999, focusing on heritable and induced forms of pulmonary hypertension. In 2022, Frédéric Perros joined the CarMeN Laboratory (Inserm U1060) in the MERISM team led by Jennifer Rieusset. Together, they explore the dialogue between the liver and the lungs and the role of mitochondria-RE interactions in this process.

PAH remains at the heart of Dr Perros’ research, which he continues to develop through a vast network of international collaborations, in particular via the international 3PH laboratory in partnership with the UniC laboratory in Porto. He is also taking advantage of his proximity to two Lyon-based centers of reference for rare diseases: the coordinating CRMR for rare pulmonary diseases and the constitutive CRMR for pulmonary hypertension, to advance his work on PAH.

His career has been marked by a relentless quest to understand the underlying mechanisms and develop new therapeutic approaches for pulmonary arterial hypertension, making him a recognized expert in the field of pulmonary vascular pathophysiology.

Expertise

• Development and characterization of animal models for pulmonary hypertension
• Preclinical studies in pulmonary hypertension, focusing on therapeutic innovation
• Exploration of genetic and epigenetic mechanisms of pulmonary hypertension, as well as associated inflammatory mechanisms.

Current Funding

• 2023: Senior Research Projects in fundamental research from the Research Foundation – Flanders (FWO): “Unraveling the cellular landscape and (epi)genetic mechanisms at single-cell resolution and the effect of Prdm16 deficiency during the pathogenesis of pulmonary arterial hypertension.” In collaboration with Aernout Luttun from the Centre for Molecular and Vascular Biology at KU Leuven, Belgium.
• 2020: International Research Project (IRP) from Inserm: “Paris – Porto Pulmonary Hypertension Collaborative Laboratory (3PH)” in collaboration with Dr. Pedro Mendes-Ferreira from the UniC laboratory in Porto, Portugal.
• 2020: ANR (French National Agency for Research) grant: “Capitalizing on activated adventitial fibroblast metabolism to treat pulmonary hypertension” (ANR-20-CE14-0006-01). In collaboration with Dr. Thomas Bertero, a researcher at IPMC (Institute of Molecular and Cellular Pharmacology) in Sophia Antipolis, France.
• 2020: Fund for Scientific Research–FNRS, PDR-Thema Cardiovascular Diseases Call 2019: “Design of a long-acting vasodilator nanomedicine for inhalation in pulmonary arterial hypertension.” In collaboration with Prof. Rita Vanbever, Research Director FNRS at the Catholic University of Louvain, Belgium.

10 Recent Publications:

1. Rachedi NS, Tang Y, Tai YY, Zhao J, Chauvet C, Grynblat J, Akoumia KKF, Estephan L, Torrino S, Sbai C, Ait-Mouffok A, Latoche JD, Al Aaraj Y, Brau F, Abélanet S, Clavel S, Zhang Y, Guillermier C, Kumar NVG, Tavakoli S, Mercier O, Risbano MG, Yao ZK, Yang G, Ouerfelli O, Lewis JS, Montani D, Humbert M, Steinhauser ML, Anderson CJ, Oldham WM, Perros F, Bertero T, Chan SY. Dietary intake and glutamine-serine metabolism control pathologic vascular stiffness. Cell Metab. 2024;36(6):1335-1350.e8.
2. Bignard J, Atassi F, Claude O, Ghigna MR, Mougenot N, Abdoulkarim BS, Deknuydt F, Gestin A, Monceau V, Montani D, Nadaud S, Soubrier F, Perros F. T-cell dysregulation and inflammatory process in Gcn2 (Eif2ak4-/-)-deficient rats in basal and stress conditions. Am J Physiol Lung Cell Mol Physiol. 2023;324(5):L609‑24.
3. Manaud G, Nossent EJ, Lambert M, Ghigna MR, Boët A, Vinhas MC, Ranchoux B, Dumas SJ, Courboulin A, Girerd B, Soubrier F, Bignard J, Claude O, Lecerf F, Hautefort A, Florio M, Sun B, Nadaud S, Verleden SE, Remy S, Anegon I, Bogaard HJ, Mercier O, Fadel E, Simonneau G, Vonk Noordegraaf A, Grünberg K, Humbert M, Montani D, Dorfmüller P, Antigny F, Perros F. Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. Am J Respir Cell Mol Biol. 2020;63(1):118‑31.
4. Hautefort A, Mendes-Ferreira P, Sabourin J, Manaud G, Bertero T, Rucker-Martin C, Riou M, Adão R, Manoury B, Lambert M, Boet A, Lecerf F, Domergue V, Brás-Silva C, Gomez AM, Montani D, Girerd B, Humbert M, Antigny F, Perros F. Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. Circulation. 2019;139(7):932‑48.
5. Ranchoux B, Bigorgne A, Hautefort A, Girerd B, Sitbon O, Montani D, Humbert M, Tcherakian C, Perros F. Gut-Lung Connection in Pulmonary Arterial Hypertension. Am J Respir Cell Mol Biol. 2017;56(3):402‑5.
6. Antigny F, Hautefort A, Meloche J, Belacel-Ouari M, Manoury B, Rucker-Martin C, Péchoux C, Potus F, Nadeau V, Tremblay E, Ruffenach G, Bourgeois A, Dorfmüller P, Breuils-Bonnet S, Fadel E, Ranchoux B, Jourdon P, Girerd B, Montani D, Provencher S, Bonnet S, Simonneau G, Humbert M, Perros F. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Circulation. 2016;133(14):1371‑85.
7. Perros F, Günther S, Ranchoux B, Godinas L, Antigny F, Chaumais MC, Dorfmüller P, Hautefort A, Raymond N, Savale L, Jaïs X, Girerd B, Cottin V, Sitbon O, Simonneau G, Humbert M, Montani D. Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. Circulation. 2015;132(9):834‑47.
8. Perros F, Ranchoux B, Izikki M, Bentebbal S, Happé C, Antigny F, Jourdon P, Dorfmüller P, Lecerf F, Fadel E, Simonneau G, Humbert M, Bogaard HJ, Eddahibi S. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. J Am Coll Cardiol. 2015;65(7):668‑80.
9. Ranchoux B, Antigny F, Rucker-Martin C, Hautefort A, Péchoux C, Bogaard HJ, Dorfmüller P, Remy S, Lecerf F, Planté S, Chat S, Fadel E, Houssaini A, Anegon I, Adnot S, Simonneau G, Humbert M, Cohen-Kaminsky S, Perros F. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation. 2015;131(11):1006‑18.
10. Ranchoux B, Günther S, Quarck R, Chaumais MC, Dorfmüller P, Antigny F, Dumas SJ, Raymond N, Lau E, Savale L, Jaïs X, Sitbon O, Simonneau G, Stenmark K, Cohen-Kaminsky S, Humbert M, Montani D, Perros F. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015;185(2):356‑71.